AMGN

As of 2026-10-26, AMGN scores 60out of 100 on QNTM’s five-factor quantitative model, a high conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. AMGN trades at $444.63, within its fair-value band.

AMGN scores 60 out of 100 on QNTM's five-factor model — a high-conviction reading — 60 puts it among the strongest factor profiles the model tracks. Its strongest factor is value at 71 (strong), where it screens cheap on the model's valuation inputs, followed by quality at 66. The weakest is volume at 43, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 12% of the Healthcare names the model scores.

On valuation, AMGN is priced near the floor of its own recent range — the cheap end on the model's valuation read. The blended composite before the macro overlay was 61. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on AMGN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where AMGN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for AMGN runs $424.33–$576.49. Current price $444.63 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.